Abstract: Compounds useful in the modulation of ion channel activity in cells are disclosed herein. This disclosure also relates to use of these compounds in the treatment of pain, and pharmaceutical compositions containing these compounds and methods for their preparation.
Type:
Grant
Filed:
April 20, 2022
Date of Patent:
January 30, 2024
Assignee:
BIONOMICS LIMITED
Inventors:
Belinda Huff, Courtney Hollis, Hamish Toop, Nathan Kuchel, Lorna Helen Mitchell, Rajinder Singh
Abstract: The present invention provides a combination therapy for treatment of a tumour in a subject. The combination therapy comprises administration of (i) an antibody directed against cancer stem cells and (ii) a checkpoint inhibitor.
Type:
Grant
Filed:
September 14, 2017
Date of Patent:
May 23, 2023
Assignee:
Bionomics Limited
Inventors:
Tina Christine Lavranos, Daniel John Inglis, Christopher L. Reyes
Abstract: Compounds useful in the modulation of ion channel activity in cells are disclosed herein. This disclosure also relates to use of these compounds in the treatment of pain, and pharmaceutical compositions containing these compounds and methods for their preparation.
Type:
Grant
Filed:
May 17, 2019
Date of Patent:
July 12, 2022
Assignee:
BIONOMICS LIMITED
Inventors:
Belinda Huff, Courtney Hollis, Hamish Toop, Nathan Kuchel, Lorna Helen Mitchell, Rajinder Singh
Abstract: The present invention relates to chemical compounds of general formula (I): which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.
Type:
Grant
Filed:
December 15, 2017
Date of Patent:
March 23, 2021
Assignee:
Bionomics Limited
Inventors:
Jonathan Bayldon Baell, Brad Sleebs, Bernard Luke Flynn, Ian Phillip Street, Nurul Quazi, Chinh Thien Bui
Abstract: The invention relates to pharmaceutical combinations comprising a vascular disrupting agent, in particular the tubulin polymerisation inhibitor BNC105, and an immunotherapeutic agent, in particular an anti-PD-L1, PD-1 or CTLA-4 antibody, and use thereof in the treatment of cancer.
Type:
Application
Filed:
November 23, 2020
Publication date:
March 11, 2021
Applicant:
BIONOMICS LIMITED
Inventors:
Gabriel KREMMIDIOTIS, Tina LAVRANOS, Daniel INGLIS
Abstract: The present invention relates generally to chemical compounds and methods for their use and preparation. In particular, the invention relates to chemical compounds which are useful in relation to the treatment of diseases, disorders or conditions which would benefit from the modulation of the alpha 7 nicotinic acetylcholine receptor (?7 nAChR). The invention also relates to the use of these compounds in methods of therapy and the manufacture of medicaments as well as compositions containing these compounds.
Type:
Application
Filed:
November 26, 2018
Publication date:
December 17, 2020
Applicant:
BIONOMICS LIMITED
Inventors:
Justin Anthony RIPPER, Patrick BAZZINI, Jean-Marie CONTRERAS, Nicolas FEICHTER, Christophe MORICE, Laurent SCHAEFFER, Cindy STAHL
Abstract: The present invention relates generally to the field of cancer biology. Some embodiments of the methods and compositions provided herein relate to administration of humanized antibodies or antigen-binding fragments thereof that specifically bind to LRG5 to treat certain cancers.
Type:
Grant
Filed:
March 21, 2017
Date of Patent:
August 18, 2020
Assignee:
BIONOMICS LIMITED
Inventors:
Christopher L. Reyes, Peter Chu, Elizabeth Doolin, Jose Iglesias
Abstract: The present disclosure relates to the biological markers SAP, SHBG, Myoglobin, MMP-9, and SCF that are predictive for patient response to treatment with a vascular disrupting agent. In particular, the present disclosure relates to biological markers predictive for cancer patient response to treatment with a vascular disrupting agent, as well as methods of treating a cancer patient with a vascular disrupting agent.
Type:
Grant
Filed:
July 2, 2015
Date of Patent:
February 18, 2020
Assignee:
BIONOMICS LIMITED
Inventors:
Gabriel Kremmidiotis, Annabell Francis Leske
Abstract: The present disclosure relates to the biological markers Ferritin and IL-8 that are predictive for patient response to treatment with a vascular disrupting agent. In particular, the present disclosure relates to biological markers predictive for cancer patient response to treatment with a vascular disrupting agent, as well as methods of treating a cancer patient with a vascular disrupting agent.
Type:
Grant
Filed:
July 2, 2015
Date of Patent:
December 31, 2019
Assignee:
Bionomics Limited
Inventors:
Gabriel Kremmidiotis, Annabell Francis Leske
Abstract: The present invention provides crystalline Forms FUM-P3, FUM-P4, MLA-P3 and MLA-P4 of compound formula 1 and related methods of treating and/or preventing a disease, such as a central nervous system disease (e.g., an anxiety disorder), using a crystalline Form FUM-P3, FUM-P4, MLA-P3 and MLA-P4 of compound formula 1 and/or pharmaceutical compositions thereof.
Type:
Grant
Filed:
August 25, 2017
Date of Patent:
April 23, 2019
Assignees:
Bionomics Limited, Ironwood Pharmaceuticals, Inc.
Inventors:
Bernard Luke Flynn, Dharam Paul, Andrew John Harvey, Vasu V. Sethuraman, Raymond E. Forslund, Song Xue, Rob Livingston, Ahmad Hashash
Abstract: The present invention relates to chemical compounds of general formula (I) which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.
Type:
Grant
Filed:
December 15, 2017
Date of Patent:
March 19, 2019
Assignee:
Bionomics Limited
Inventors:
Jonathan Bayldon Baell, Brad Sleebs, Bernard Luke Flynn, Ian Phillip Street, Nurul Quazi, Chinh Thien Bui
Abstract: The present invention relates generally to substituted benzofurans, benzothiophenes, and indoles and their use as tubulin polymerization inhibitors.
Type:
Grant
Filed:
April 28, 2016
Date of Patent:
February 26, 2019
Assignee:
BIONOMICS LIMITED
Inventors:
Jason Hugh Chaplin, Gurmit Sing Gill, Damian Wojciech Grobelny, Bernard Luke Flynn, Gabriel Kremmidiotis
Abstract: The present invention relates to cancer markers that are predictive for cancer patent response to treatment with an m TOR inhibitor and a vascular disrupting agent. The present invention further relates to methods of treating a cancer patient subpopulation with a combination of an m TOR inhibitor and a vascular disrupting agent.
Abstract: The present disclosure relates to the biological markers SAP, SHBG, Myoglobin, MMP-9, and SCF that are predictive for patient response to treatment with a vascular disrupting agent. In particular, the present disclosure relates to biological markers predictive for cancer patient response to treatment with a vascular disrupting agent, as well as methods of treating a cancer patient with a vascular disrupting agent.
Type:
Application
Filed:
July 2, 2015
Publication date:
July 12, 2018
Applicant:
BIONOMICS LIMITED
Inventors:
Gabriel KREMMIDIOTIS, Annabell Francis LESKE
Abstract: The present disclosure relates to the biological markers Ferritin and IL-8 that are predictive for patient response to treatment with a vascular disrupting agent. In particular, the present disclosure relates to biological markers predictive for cancer patient response to treatment with a vascular disrupting agent, as well as methods of treating a cancer patient with a vascular disrupting agent.
Type:
Application
Filed:
July 2, 2015
Publication date:
July 12, 2018
Applicant:
BIONOMICS LIMITED
Inventors:
Gabriel KREMMIDIOTIS, Annabell Francis LESKE
Abstract: The invention relates to pharmaceutical combinations comprising a vascular disrupting agent, in particular the tubulin polymerisation inhibitor BNC105, and an immunotherapeutic agent, in particular an anti-PD-L1, PD-1 or CTLA-4 antibody, and use thereof in the treatment of cancer.
Type:
Application
Filed:
June 10, 2016
Publication date:
June 14, 2018
Applicant:
BIONOMICS LIMITED
Inventors:
Gabriel KREMMIDIOTIS, Tina LAVRANOS, Daniel INGLIS
Abstract: The present disclosure provides methods for treating chronic lymphocytic leukemia (CLL) with medicaments useful for same. The medicaments can be pharmaceutical compositions or kits comprising compounds of formula (I) or a salt, solvate or prodrug thereof. Specific compounds of the invention include 2-methyl-7-hydroxy-3-(3,4,5-trimethoxybenzoyl)-6-methoxybenzofuran which is also known as BNC105 and disodium 6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzofuran-7-yl phosphate which is also known as BNC 105P.
Abstract: The present invention relates to chemical compounds of general formula (I) which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.
Type:
Grant
Filed:
January 4, 2017
Date of Patent:
May 22, 2018
Assignee:
Bionomics Limited
Inventors:
Jonathan Bayldon Baell, Brad Sleebs, Bernard Luke Flynn, Ian Phillip Street, Nurul Quazi, Chinh Thien Bui
Abstract: The present invention relates to chemical compounds of general formula (I) which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.
Type:
Application
Filed:
December 15, 2017
Publication date:
April 19, 2018
Applicant:
Bionomics Limited
Inventors:
Jonathan Bayldon Baell, Brad Sleebs, Bernard Luke Flynn, Ian Phillip Street, Nurul Quazi, Chinh Thien Bui